petosemtamab subcutaneous (GEN-1158 SC) / Genmab - LARVOL DELTA

November 2025 therapeutic delivery: industry update. (PubMed, Ther Deliv) - "November 2025 saw the approval of a number of products which employ a variety of delivery technologies including Johnson and Johnson's DARZALEX FASPRO (with Haloyzyme's ENHAZE), Merck's KEYTRUDA QLEX, and Regeneron's EYLEA HD. Halozyme also announced a collaboration with the Dutch company Merus, for the development of a subcutaneous formulation of petosemtamab. Positive clinical trial data was announced for a number of companies including EyePoint, Tiziana, Nasus, and Tonix."

Biomarker • Clinical • Journal • Observational data • Retrospective data • Review

Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab (PRNewswire) - "Under the collaboration, Merus has licensed Halozyme's ENHANZE drug delivery technology, for the development and potential commercialization of subcutaneous administration of petosemtamab, an EGFR x LGR5 bispecific antibody...Under the terms of the agreement, Merus will make an upfront payment to Halozyme, and potential future milestone payments related to commercial and sales attainment, if approved."

Licensing / partnership • Squamous Cell Carcinoma of Head and Neck